C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib

BACKGROUND AND AIM: Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:PLoS One
Päätekijät: Hayashi, Tsuguru, Shibata, Michihiko, Oe, Shinji, Miyagawa, Koichiro, Honma, Yuichi, Harada, Masaru
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Public Library of Science 2020
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755182/
https://ncbi.nlm.nih.gov/pubmed/33351844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0244370
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia